ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Belgian drug company UCB will buy an Eli Lilly and Company research site in Windlesham, England, that the US firm shut down last year. UCB plans to renovate the campus before relocating its UK operations from Slough, England, as part of a plan to invest about $1.3 billion in the UK over 5 years. The facility will support 650 jobs and will be one of UCB’s three R&D hubs, including ones in Belgium and the US.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X